Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands

ABSTRACT: Checkpoint markers and immune checkpoint inhibitors have been increasingly identified and developed as potential immunotherapeutic targets in various human cancers. Despite valuable efforts to discover novel immune checkpoints and their ligands, the precise roles of their therapeutic functions, as well as the broad identification of their counterpart receptors, remain to be addressed. In this context, it has been suggested that various putative checkpoint receptors can be induced upon activation. In the tumor microenvironment, T cells, as crucial immune response against malignant diseases as well as other immune central effector cells, such as natural killer cells, are regulated via co-stimulatory or co-inhibitory signals from immune or tumor cells. Studies have shown that exposure of T ce

SUBMITTER:  

PROVIDER: S-EPMC10469281 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature